Please assess the completion status of the following clinical trial:

Trial Title: Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>18 years and \<80 years.~* Patient is, in the investigator(s) opinion, willing and able to comply with the protocol requirements.~* Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.~* Male patient agrees to use an acceptable method for contraception (i.e. condom or abstinence) for the duration of the study.~Female of childbearing potential agrees to use two acceptable methods for contraception \[implant, levonorgestrel-releasing intrauterine system (IUS), medroxyprogesterone acetate depot, tubal sterilization, sexual intercourse with a vasectomised male partner only (vasectomy must be confirmed by two negative semen analyses), ovulation inhibitory progesterone-only pills (i.e. desogestrel)\] or absolute and continuous sexual abstinence.~* Patient has measurable disease, defined as follows: any quantifiable serum monoclonal protein value (generally, but not necessarily, ≥ 0.5 g/dL of M-protein) and, where applicable, urine light-chain excretion of \>200 mg/24 hours; only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved Free Light Chain (FLC) levels must be \> 10 mg/dL. Less than 10% of oligo- or non-secretory MM patients with free light chains will be admitted to this study in order to maximize interpretation of benefit results.~* Patient receiving lenalidomide maintenance therapy as part of first line treatment (concomitant use of prednisone is accepted) and has experienced a biochemical relapse, with evidence of progressive disease defined as an increase of 25% from lowest response value in any one or more of the following: serum M-component (absolute increase must be ≥0.5 g/100 ml) and/or urine M-component (absolute increase must be ≥200 mg per 24 hours) only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels must be \>10 mg/dL (35).~* Patient who received as first line treatment a bortezomib-based therapy, including lenalidomide maintenance during the same line of therapy, can be included in the trial.~* Patient has a life-expectancy \> 3 months~* Patient has not a currently active malignancy, other than non melanoma skin cancer and carcinoma in situ of the cervix, and has not invasive malignancies within the past 5 years.~* No history of allergic reactions attributed to study agents~* Patient has the following laboratory values within 28 days before baseline day 1 of the cycle 1:~  1. absolute neutrophil count (ANC) \> 1 x 10\^9/L~ 2. platelet count \> 75 x 10\^9/L~ 3. haemoglobin \> 8 g/dl.~ 4. aspartate transaminase (AST): \< 2 x the upper limit of normal (ULN).~ 5. alanine transaminase (ALT): \< 2 x the ULN.~Exclusion Criteria:~* Pregnant or lactating females.~* Patient with Creatinine Clearance (CrCl) \< 45 mL/minute~* Patient with peripheral neuropathy ≥ Grade 2~* Subject with any one of the following:~* Congestive heart failure (NY Heart Association Class III or IV)~* Myocardial infarction within 12 months prior to starting study treatment~* Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris~* Any significant medical disease or conditions (e.g. pulmonary disease, infection) that, in the investigator's opinion, may interfere with protocol adherence or subject's ability to give informed consent or could place the subject at unacceptable risk.~* Clinical active infectious hepatitis type A, B, C or HIV Acute active infection requiring antibiotics or infiltrative pulmonary disease~* Contraindication to any of the required drugs or supportive treatments.~* Known allergy to any of the study medications, their analogues, or excipients in the various formulations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ARM pom-dex Early (A-I) (Type: ACTIVE_COMPARATOR): Patients will receive treatment at biochemical relapse with pom-dex Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
- ARM pom-cyclo-dex Early(B-I) (Type: EXPERIMENTAL): Patients will receive treatment at biochemical relapse with pom-cyclo-dex Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
- ARM pom-dex Late (A-II) (Type: EXPERIMENTAL): Patients will be randomized at biochemical relapse and they will start treatment with pom-dex at the onset of CRAB symptoms/significant paraprotein increase.~Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
- ARM pom-cyclo-dex Late (B-II) (Type: ACTIVE_COMPARATOR): Patients will be randomized at biochemical relapse and they will start treatment with pom-cyclo-dex at the onset of CRAB symptoms/significant paraprotein increase.~Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance

Based on this trial design, predict the completion outcome and termination type (if applicable).